Aethlon updates share count after warrant exercises

Aethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026.

Rhea-AI Filing Summary

Aethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. The company stated that all previously outstanding pre-funded warrants have now been exercised, simplifying its capital structure by converting those warrant rights into common shares.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aethlon Medical (AEMD) announce in its March 2026 8-K?

Aethlon Medical announced that all previously outstanding pre-funded warrants have been exercised. As a result, it now has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026, clarifying its current equity capitalization.

How many Aethlon Medical (AEMD) shares are outstanding after warrant exercises?

After recent exercises of certain pre-funded warrants, Aethlon Medical reported 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. This figure reflects the full conversion of all previously outstanding pre-funded warrants into common shares.

What happened to Aethlon Medical’s previously outstanding pre-funded warrants?

Aethlon Medical stated that all previously outstanding pre-funded warrants have been exercised. This means those derivative securities have been fully converted into common stock, leaving no pre-funded warrants outstanding as of March 16, 2026, according to the company’s disclosure.

Does Aethlon Medical’s 8-K mention any remaining pre-funded warrants?

The company reported that all previously outstanding pre-funded warrants have been exercised. This indicates there are no remaining pre-funded warrants outstanding, and the related rights have been converted into common shares as of March 16, 2026, based on the company’s statement.

What is the significance of March 16, 2026 for Aethlon Medical’s share count?

March 16, 2026 is the date Aethlon Medical used to report its updated share count. The company disclosed that it had 1,569,110 shares of common stock outstanding as of the close of business on that date, following exercises of certain pre-funded warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 09:15 AM EDT Learn about SEC filing dates

false 0000882291 0000882291 2026-03-16 2026-03-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2026

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11555 Sorrento Valley Road, Suite 203 San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (619) 941-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		AEMD		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Following recent exercises of certain pre-funded warrants, Aethlon Medical, Inc. has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026. As such, all previously outstanding pre-funded warrants have been exercised.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 17, 2026	Aethlon Medical, Inc.
	By:	/s/ James B. Frakes
		James B. Frakes Chief Executive Officer and Chief Financial Officer

3

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB